Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus.

Antimicrobial Agents and Chemotherapy
Wen WangZhengyu Yuan

Abstract

Peptide deformylase (PDF) is an essential enzyme in both gram-negative and gram-positive bacteria. It hydrolyzes formylated N-terminal peptides to generate free N-terminal peptides during the process of protein maturation. Inhibition of this enzyme results in cessation of bacterial growth. We have examined the effect of a potent PDF inhibitor, LBM-415 (also known as VIC-104959), on the proteomes of Staphylococcus aureus and Streptococcus pneumoniae using two-dimensional electrophoresis. Both S. aureus and S. pneumoniae showed accumulation of many N-terminal formylated peptides/proteins upon PDF inhibition. In S. pneumoniae, formylated peptide/protein accumulation was time dependent. Following inhibition, subsequent removal of the inhibitor resulted in deformylation of formylated peptides/proteins; this recovery process was also time dependent. If instead the inhibited cells were maintained in the presence of sub-MIC levels of the PDF inhibitor, the formylated peptides/proteins remained for a much longer time, which correlated with a prolonged postantibiotic effect in vitro. These observations may have broader implications for the application of this class of antibiotics in vivo.

References

Mar 14, 1972·Journal of Molecular Biology·D HousmanH F Lodish
Sep 25, 1973·Journal of Molecular Biology·L A Ball, P Kaesberg
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·D L ShinabargerJ M Buysse
Mar 21, 2001·Antimicrobial Agents and Chemotherapy·C M ApfelW Keck
Aug 15, 2001·Antimicrobial Agents and Chemotherapy·P MargolisJ Trias
Sep 8, 2001·Drug Discovery Today·Z YuanR J. White
Feb 27, 2003·Antimicrobial Agents and Chemotherapy·Julia Elisabeth BandowMichael Hecker
Mar 11, 2003·Proteomics·Julia Elisabeth BandowMichael Hecker
Feb 18, 2004·Protein Expression and Purification·Shari SpectorRobert T Sauer
Oct 19, 2004·The Journal of Clinical Investigation·Mona D LeeDavid A Scheinberg
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Thomas R FritscheRonald N Jones
Jul 19, 2005·Current Medicinal Chemistry·R JainZ Yuan

❮ Previous
Next ❯

Citations

May 19, 2010·Archives of Microbiology·Lúcio F C FerrazLaura M M Ottoboni
Jul 9, 2008·BMC Genomics·Christina J BrandnerKamil Onder
Jun 18, 2009·Expert Opinion on Therapeutic Targets·Anshika SharmaSadhna Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.